Form D · Biotechnology
KINETA, INC./DE
Seattle, WA · CIK 0001445283
Offering snapshot reported Oct 20, 2023 · SEC filing
- Reported sold
- $0 Offering amount: $2.89M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 3, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 20, 2023 | Initial | $0 | No comparison | 1 | SEC filing |
| Dec 29, 2022 | Initial | $7,500,000 | No comparison | 17 | SEC filing |
| Jan 6, 2021 | Initial | $33,599,895 | No comparison | 16 | SEC filing |
| Sep 15, 2015 | Initial | $21,999,992 | No comparison | 9 | SEC filing |
| Sep 15, 2015 | Amendment | $15,000,000 | $10,000,000vs Oct 7, 2014 | 8 | SEC filing |
| Oct 7, 2014 | Amendment | $5,000,000 | $1,987,729vs Aug 14, 2014 | 7 | SEC filing |
| Aug 14, 2014 | Initial | $3,012,271 | No comparison | 5 | SEC filing |
| Jun 2, 2011 | Amendment | $70,623,000 | No comparison | 7 | SEC filing |
| Sep 10, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $210K
- Finders' fees
- $0
- Form D file number
- 021-495306
Concurrent with a registered offering, warrants were issued to purchase up to an aggregate of 890,208 shares of common stock at $3.25 per share. Gross proceeds will come from the exercise of the warrants to the extent such warrants are exercised for cash.
Represents the 7% cash fee paid to the placement agent in the concurrent registered direct offering referenced in item 13.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co., LLC | 375 |
Source: Form D, filed Oct 20, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Patricia L. Allen | Director |
| David Arkowitz | Director |
| Keith A. Baker | Executive |
| Keith A. Baker | Executive |
| M. James Barrett | Director |
| Raymond Bartoszek | Director |
| Michael Casey | Executive |
| Meenu Chhabra | Director, Executive |
| N. Anthony Coles | Director, Executive |
| Bernard Davitian | Director |
| Kim C. Drapkin | Director |
| Kimberlee C. Drapkin | Director |
| Scott J. Dylla | Director |
| Marion R. Foote | Director |
| Marion R. Foote | Director |
| Jeffrey Goldberg | Executive |
| Thierry Guillaudeux | Executive |
| Markus Haeberlein | Executive |
| Richard A. Heyman | Director |
| Shawn P. Iadonato | Director, Executive |
| Jeffery W. Kelly | Director |
| Pauline Kenny | Executive |
| Stephen Knight | Director |
| Stephen Knight, M.D. | Director |
| Irena Melnikova | Promoter |
| Christopher K. Mirabelli | Director |
| Paulash Mohsen | Executive |
| Walter Newman | Executive |
| Richard Peters | Director |
| Craig W. Philips | Executive |
| Craig W. Philips | Executive |
| Cecil B. Pickett | Director |
| Peter H. Reinhart | Director, Executive, Promoter |
| Brigitte Robertson | Executive |
| Pauline Jen Ryan | Executive |
| Lauren Silverman | Director |
| Lauren Silverman, Ph.D. | Director |
| Henry B. Skinner | Director |
| Janet Smart | Executive |
| Nadia Ustariz | Executive |
| Christopher T. Walsh | Director |
| Conor Walshe | Director |
| Alan Walts, Ph.D. | Director |
| Lynne Zydowsky | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
219 Terry Ave. N. Suite 300
Seattle, WA, 98109
Seattle, WA, 98109